Evidence map›Paper›PMID 27521344›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2016

New Murine Model of Early Onset Autoimmune Thyroid Disease/Hypothyroidism and Autoimmune Exocrinopathy of the Salivary Gland.

Timothy Daniel Kayes, Gary A Weisman, Jean M Camden, Lucas T Woods, Cole Bredehoeft, Edward F Downey, James Cole, Helen Braley-Mullen

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Therapeutic potential for P2YPurinergic signalling · 2023
    Review
  3. Early Dry Eye Disease Onset in a NOD.H-2h4 Mouse Model of Sjögren's Syndrome.Investigative ophthalmology & visual science · 2022
    Article
  4. The NOD Mouse Beyond Autoimmune Diabetes.Frontiers in immunology · 2022
    Review
  5. Review
  6. P2YArchives of oral biology · 2021
    Article
  7. Article
  8. P2YOral diseases · 2018
    Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Timothy Daniel KayesDepartment of Medicine, University of Missouri, Columbia, MO 65212;
Gary A WeismanDepartment of Biochemistry, University of Missouri, Columbia, MO 65211; Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO 65211; and.
Jean M CamdenDepartment of Biochemistry, University of Missouri, Columbia, MO 65211; Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO 65211; and.
Lucas T WoodsDepartment of Biochemistry, University of Missouri, Columbia, MO 65211; Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO 65211; and.
Cole BredehoeftDepartment of Medicine, University of Missouri, Columbia, MO 65212;
Edward F DowneyDepartment of Medicine, University of Missouri, Columbia, MO 65212;
James ColeDepartment of Medicine, University of Missouri, Columbia, MO 65212;
Helen Braley-MullenDepartment of Medicine, University of Missouri, Columbia, MO 65212; Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65212 mullenh@health.missouri.edu.

Funding

VIP RECEPTORS AND SUBMANDIBULAR GLAND FUNCTIONR01DE007389 · NIDCR · UNIVERSITY OF MISSOURI-COLUMBIA · PI WEISMAN, GARY ANDREW · 1988 to 2020
$7.6M
Restoring Salivary Gland Function by Reducing Nucleotide-induced InflammationR01DE023342 · NIDCR · UNIVERSITY OF MISSOURI-COLUMBIA · PI WEISMAN, GARY ANDREW · 2014 to 2018
$2.9M
Thyroid Epithelial Cell Hyperplasia: Mechanisms of InductionR01AI074857 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI MULLEN, HELEN B · 2009 to 2012
$1.4M
Thyroid Epithelial Cell Hyperplasia: Mechanisms of InductionR56AI074857 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI MULLEN, HELEN B · 2008 to 2008
$358k
NIAID NIH HHS R01 AI074857NIAID NIH HHS R56 AI074857NIDCR NIH HHS R01 DE007389NIDCR NIH HHS R01 DE023342
6 · The paper itself

Abstract

Sixty to seventy percent of IFN-γ(-/-) NOD.H-2h4 mice given sodium iodide (NaI)-supplemented water develop a slow onset autoimmune thyroid disease, characterized by thyrocyte epithelial cell (TEC) hyperplasia and proliferation (H/P). TEC H/P develops much earlier in CD28(-/-) mice and nearly 100% (both sexes) have severe TEC H/P at 4 mo of age. Without NaI supplementation, 50% of 5- to 6-mo-old CD28(-/-)IFN-γ(-/-) mice develop severe TEC H/P, and 2-3 wk of NaI is sufficient for optimal development of severe TEC H/P. Mice with severe TEC H/P are hypothyroid, and normalization of serum thyroxine levels does not reduce TEC H/P. Activated CD4(+) T cells are sufficient to transfer TEC H/P to SCID recipients. Thyroids of mice with TEC H/P have infiltrating T cells and expanded numbers of proliferating thyrocytes that highly express CD40. CD40 facilitates, but is not required for, development of severe TEC H/P, as CD40(-/-)IFN-γ(-/-)CD28(-/-) mice develop severe TEC H/P. Accelerated development of TEC H/P in IFN-γ(-/-)CD28(-/-) mice is a result of reduced regulatory T cell (Treg) numbers, as CD28(-/-) mice have significantly fewer Tregs, and transfer of CD28(+) Tregs inhibits TEC H/P. Essentially all female IFN-γ(-/-)CD28(-/-) NOD.H-2h4 mice have substantial lymphocytic infiltration of salivary glands and reduced salivary flow by 6 mo of age, thereby providing an excellent new model of autoimmune exocrinopathy of the salivary gland. This is one of very few models where autoimmune thyroid disease and hypothyroidism develop in most mice by 4 mo of age. This model will be useful for studying the effects of hypothyroidism on multiple organ systems.

Indexed as

Disease Models, AnimalAnimalsAutoimmune DiseasesCD28 AntigensCD40 AntigensCells, CulturedEpithelial CellsHyperplasiaHypothyroidismInterferon-gammaIodineMiceMice, Inbred C57BLSalivary Gland DiseasesThyroid DiseasesThyroid GlandCD28 AntigensCD40 AntigensInterferon-gammaIodineThyroxine

Identifiers

PMID27521344
PMCPMC5010957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.